In silico and in vivo experiment of soymilk peptide (tetrapeptide - FFYY) for the treatment of hypertension.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- In silico and in vivo experiment of soymilk peptide (tetrapeptide - FFYY) for the treatment of hypertension.
- Published In:
- Peptides, 175, 171170 (2024)
- Authors:
- Alauddin, Md, Amin, Md Ruhul, Siddiquee, Muhammad Ali, Hiwatashi, Kazuyuki, Shimakage, Atsushi, Takahashi, Saori, Shinbo, Mamoru, Komai, Michio, Shirakawa, Hitoshi
- Database ID:
- RPEP-07707
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07707APA
Alauddin, Md; Amin, Md Ruhul; Siddiquee, Muhammad Ali; Hiwatashi, Kazuyuki; Shimakage, Atsushi; Takahashi, Saori; Shinbo, Mamoru; Komai, Michio; Shirakawa, Hitoshi. (2024). In silico and in vivo experiment of soymilk peptide (tetrapeptide - FFYY) for the treatment of hypertension.. Peptides, 175, 171170. https://doi.org/10.1016/j.peptides.2024.171170
MLA
Alauddin, Md, et al. "In silico and in vivo experiment of soymilk peptide (tetrapeptide - FFYY) for the treatment of hypertension.." Peptides, 2024. https://doi.org/10.1016/j.peptides.2024.171170
RethinkPeptides
RethinkPeptides Research Database. "In silico and in vivo experiment of soymilk peptide (tetrape..." RPEP-07707. Retrieved from https://rethinkpeptides.com/research/alauddin-2024-in-silico-and-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.